Vivek Sharma – CEO, Piramal Pharma Solutions (PPS)
Vivek Sharma, CEO of Piramal Pharma Solutions (PPS), one of the world’s leading CDMOs with a presence in North America, Europe, and Asia, provides insights into the main trends shaping…
Piramal Pharma Solutions Inc. provides integrated analytical, formulation development, and pharmaceutical manufacturing services. The company offers drug product manufacturing services for liquid and lyophilized parenteral, process development and optimization, terminal sterilization, pilot scale manufacturing (aseptic and non-aseptic), and niche commercial products; and pre-clinical to Phase III manufacturing services for animal safety/toxicity studies, human clinical products, and veterinary products.
It also delivers customer-centric solutions in the field of antibody-drug conjugates to pharmaceutical companies worldwide. The company was founded in 2007 and is based in Lexington, Kentucky. As of January 16, 2015, Piramal Pharma Solutions Inc. operates as a subsidiary of Piramal Healthcare, Inc.
Vivek Sharma, CEO of Piramal Pharma Solutions (PPS), one of the world’s leading CDMOs with a presence in North America, Europe, and Asia, provides insights into the main trends shaping…
As rare disease regulation moves from the margins to the mainstream of global health policy, India faces both a challenge and an opportunity: how to align with international best practices…
In an era of rapid scientific breakthroughs, global regulators are navigating new challenges—accelerating approvals, harmonising standards, and integrating digital tools—while balancing safety, efficacy, and access. Throughout 2024, PharmaBoardroom spoke with…
Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year,…
Shagun Sharma, Vipul Kumar Gupta, and Helene Sou of Takeda, writing in the December 2024 edition of DIA’s Global Forum magazine, look at how updates to India’s regulatory framework for…
Contributing to the October 2024 edition of DIA’s Global Forum magazine, Stephanie Rosner of DIA and Martin Hodosi and Rosanna Lim of Kearney highlight the discussions from DIA’s multistakeholder Responsible…
Contributing to the September 2024 edition of DIA’s Global Forum magazine, Siva Kumar Buddha of Indegene reviews the challenges of risk communication and minimization in India’s healthcare sector. In…
A run-through of some of the most striking recent stories from pharma in the dynamic Asia-Pacific region, including Japan’s attempts to bring back Big Pharma investment; UCB’s decision to divest…
Poised to overtake Japan and become the world’s fourth-largest economy by 2025 according to the latest International Monetary Fund estimates and now registering heady year-on-year growth rates exceeding eight percent,…
Halewood Laboratories’ Sanchit Chaturvedi discusses the impact of taking on a leadership role in a challenging personal moment; the company’s enduring commitment to innovation and quality; and its planned expansion…
In the words of Founder and Chairman Kaushik Chaturvedi, Halewood Labs’ success since its foundation in the early 1980s can be put down to three key factors: vision and commitment,…
Managing Director Dr Sharvil Patel outlines the objectives behind the rebranding of the Indian pharma company from Zydus Cadila to Zydus Lifesciences, provides insights into the importance of the US…
India faces a significant diabetes burden, with some observers even labelling the country ‘The Diabetes Capital of the World’. Around 101.4 million adults, or 11 percent of the Indian population,…
See our Cookie Privacy Policy Here
